top of page
News, Events and Updates
Search
Anavex Reports Fiscal Second Quarter 2016 Financial Results
May 10, 2016
Speaker Session: BIO 2016 International Convention
May 2, 2016
U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
Apr 7, 2016
33rd Camerino-Cyprus Symposium
Apr 5, 2016
Anavex Annual Stockholders Meeting
Apr 5, 2016
Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
Mar 13, 2016
AF710B, a Concomitant Activator of M1 Muscarinic and Sigma-1 Receptors: Possibly Disease-Modifying
Mar 13, 2016
Anavex Announces 2-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response
Mar 10, 2016
Assessment of ANAVEX 2-73 in a MECP2 Rett Syndrome Mouse Model
Feb 26, 2016
30
31
32
33
34
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
